MedPath

Comparing High Versus Low Dose of Oxytocin, in Gravida Women With BMI 30 and Above Which Are Undergoing Induction of Labor

Phase 4
Not yet recruiting
Conditions
Induction of Labor
Augmentation of Labor
Interventions
Drug: Oxytocin Grindeks 10 IU/ml- solution for injection
Registration Number
NCT06990217
Lead Sponsor
HaEmek Medical Center, Israel
Brief Summary

The goal of this clinical trial is to compare between higher and lower dose of oxytocin to induce delivery in obese women. Researches will compare between low and high doses of oxytocin. the study group will use high dose of oxytocin (20 units in 1000 ml) versus the control group which will use low dose of oxytocin (10 units of oxytocin in 1000 ml)

Detailed Description

the duration and the progression of the first stage of labor is slower in obese women and oxytocin seems to be less effective in the treatment of protracted labor in obese women. There is no consensus in the literature about the optimal oxytocin dose. Hence, the objective of this study is to compare 2 oxytocin regimens, low VS high dose among obese women who need induction or augmentation of labor.

Women at term (37-42 weeks), requiring the use of oxytocin for induction of labor or for augmentation of labor. Who are obese (BMI 30 and above), Viable singleton pregnancies with Cephalic presentation. After their consent, will be randomization: in a 1:1 allocation.

Group 1 (control) will receive a low dose- 10 units of oxytocin in 1000 ml STD. Starting rate 12 ml/h increase dose by 12 ml/h every 30 min up to 5 contractions / 10 min. Max dose 120 ml/h.

Group 2 (study) will receive a high dose- 20 units of oxytocin in 1000 ml STD. Starting rate 12 ml/h increase dose by 12 ml/h every 30 min up to 5 contractions / 10 min. Max dose 120 ml/h.

The primary outcome of the study is the time from the start of oxytocin to delivery

Statistical analysis Mean time interval from initiation of augmentation/ induction with oxytocin until delivery was eight hours (±240 minutes), based on previous observation at the delivery ward. The aim of study is to demonstrate a difference of 2 hours between the 2 groups with an alpha of 0.05 and a power of 80%, a sample size of 64 women per group is required. The primary analysis will be performed on the groups as allocated, that is, by the intention to treat, including all women as randomized.

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
Female
Target Recruitment
130
Inclusion Criteria
  • Women at term (37-42 weeks), requiring the use of oxytocin for induction of labor or for augmentation of labor.
  • BMI 30 and above
  • Viable singleton pregnancies
  • Cephalic presentation.
  • No contraindication for vaginal delivery
Exclusion Criteria
  • Women with previous cesarean delivery
  • Multiple pregnancy
  • Multiple fetal malformations
  • IUFD

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
High dose oxytocinOxytocin Grindeks 10 IU/ml- solution for injectionThis arm of the study will receive high dose oxytocin - 20 units of oxytocin in 1000 ml STD. Starting rate 12 ml/h increase dose by 12 ml/h every 30 min up to 5 contractions / 10 min. Max dose 120 ml/h.
Low dose oxytocinOxytocin Grindeks 10 IU/ml- solution for injectionThis arm of the study will receive low dose oxytocin- - 10 units of oxytocin in 1000 ml STD. Starting rate 12 ml/h increase dose by 12 ml/h every 30 min up to 5 contractions / 10 min. Max dose 120 ml/h.
Primary Outcome Measures
NameTimeMethod
Time from the start of oxytocin to deliveryfrom the start of induction till delivery

our hypothesis that high dose of oxytocin shortens the time from the start of induction to delivery

Secondary Outcome Measures
NameTimeMethod
Maternal satisfactionwill be assessed up to 1 day after delivery

We will assess maternal satisfaction using a scale - Birth Satisfaction Scale-Revised (BSS-R). a five pont scale, 0 is totally disagree, 5 totally agree.

Neonatal outcomesup to 1 week

neonatal PH\<7.1

Apgar scoreat 1, 5 and 10 minutes

minimum 0 and maximum 10. zero is bad outcome 10 is good outcome

GTPAL systemat enrollment

GTPAL system assessed by questionnaire

maternal weightat enrollment

weight before pregnancy, weight at admission

maternal heightat enrollment

height

mode of deliveryat delivery
Maternal ageat enrollment

maternal age at enrollment

uterine ruptureup to 6 weeks after delivery
perineal tearsduring delivery
intrapartum feverduring labor
PPHup to 6 weeks
length of postpartum stayperinatal.

normally a gravida's length of stay after normal delivery is 48 hours and after c-section is up to 3-4 days.

Trial Locations

Locations (1)

Haemek Medical Center

🇮🇱

Afula, Israel

© Copyright 2025. All Rights Reserved by MedPath